

Adaptive immunity in cancer immunology and therapeutics

Emma L Spurrell¹ and Michelle Lockley²

¹Whittington Health NHS Trust, Magdala Avenue, London N19 5NF, UK

²Barts Cancer Institute, Queen Mary University of London Charterhouse Square, London EC1M 6BQ, UK

Correspondence to: Emma Spurrell. Email: emmaspurrell@doctors.org.uk

Abstract

The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and survival. Tumour-associated antigens (TAAs) are one of the fundamental triggers of the immune response. They are important because they activate, via major histocompatibility complex (MHC), the T cell response, an important line of defense against tumorigenesis. However, the persistence of tumours despite host immunity implies that tumour cells develop immune avoidance. An example of this is the up-regulation of inhibitory immune checkpoint proteins, by tumours, which induces a form of self-tolerance. The majority of monoclonal antibodies in clinical practice have been developed to target tumour-specific antigens. More recently there has been research in the down-regulation of immune checkpoint proteins as a way of increasing anti-tumour immunity.

Keywords: *adaptive immunity, tumour-associated antigens, CTLA4, PD-1, PDL-1, monoclonal antibody, immune tolerance*

Published: 02/07/2014

Received: 11/02/2014

ecancer 2014, 8:441 DOI: 10.3332/ecancer.2014.441

Copyright: © the authors; licensee ecancermedicalsecience. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Tumours do not grow in isolation, but exist within a complex network of structures, cells, and chemical signals ranging from epithelial cells, stroma, blood, and lymphatic vasculature, immune cells, cytokines, and chemokines. The vast genetic alterations characteristic of tumours produce a number of tumour antigens that enable the immune system to differentiate tumour cells from normal cells. Counter to this, tumour cells have developed mechanisms by which to evade host immunity in their constant quest for growth and survival.

A typical tumour structure includes the tumour core, the invasive margin, and the surrounding stromal and lymphoid components. Within all of these is a heterogeneous immune infiltrate that can be diverse from patient to patient, as well as within different metastatic sites of a single patient. A typical tumour will contain all immune cell-types, including macrophages, dendritic cells, natural killer (NK) cells, mast cells, B cells, and T cells [including T helper 1 (T_H1), T helper 2 (T_H2), regulatory T cells (T_{Reg}) and cytotoxic T cells]. Within this immune milieu there are components that are beneficial, as well as components that are deleterious to the patient. Histopathological analysis of tumours has identified that different immune cells may be found in different locations within a tumour. The variation in density and distribution of immune cells within tumours is thought to affect clinical outcome [1]. Although the innate immune response plays a role in anti-tumour immunity, detailed discussion is beyond the scope of this review, which will focus on the adaptive immune response.

Adaptive immunity and the control of tumour growth

Tumour-associated antigens (TAAs) are one of the fundamental triggers of the immune response. They are important because they activate, via, major histocompatibility complex (MHC), the T cell response, an important line of defense against tumourigenesis.

TAAs that are recognised by T cells are classified in [Table 1](#). The review is restricted to TAAs recognised by T cells as these represent the main therapeutic targets in oncology. Although TAAs arise by different mechanisms, they are all presented to T cells via MHC class I or II on antigen presenting cells. This triggers T cell activation with expression of co-stimulatory molecules and secretion of chemokines and cytokines. The effect is to drive clonal expansion of the T cell as well as to recruit other immune effector cells (including components of the innate immune system). CD4 T cells, also known as T helper cells, secrete cytokines and chemokines that regulate different aspects of the immune response. T_H1 CD4 T cells activate CD8 T cells, favouring cellular immunity. T_H2 CD4 T cells act on B cells, favouring humoral immunity. CD8 T cells, which are directly cytotoxic, are activated both by direct presentation of antigen, via MHC class I, or via CD4 T cell-mediated activation. Ultimately, the tumour cell is destroyed by direct cell-mediated cytotoxicity as well as an indirect antibody complement-mediated cytotoxicity [2].

Immune editing and evasion

The persistence of tumours despite host immunity implies that tumour cells develop immune avoidance. There are a number of mechanisms by which this may occur. Some tumours have been demonstrated to lose expression of MHC molecules making them unable to present tumour antigens, thus evading T cell recognition. Some tumours secrete immunosuppressive cytokines, e.g., IL-10. There are tumours that grow within their own immune-privileged site by generating physical barriers, e.g., collagen and fibrin, thus making them invisible to the immune system.

Tumours can also evade the immune response by up-regulating inhibitory molecules and inducing a form of self-tolerance [4]. Immune checkpoints are vital for maintenance of self-tolerance and protection of normal tissue from damage at the site of an immune response. Specific regulatory cells and inhibitory receptors achieve immune tolerance. Regulatory T cells (T_{Reg}) are immunosuppressive. They secrete inhibitory cytokines, such as IL-10 and TGF β , resulting in down-regulation of effector B and T cells [5]. T cells rely on co-stimulatory signals to generate an immune response. Inhibition of co-stimulatory signals helps to maintain immune tolerance. Cytotoxic T-lymphocyte associated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are both inhibitory receptors involved in down-regulation of immune responses.

There is currently a lot of interest in the down-regulation of immune checkpoint proteins as a way of increasing anti-tumour immunity. Antibodies against CTLA-4 and PD-1 have been tested in therapeutic trials, which are discussed below.

Table 1. Classification of tumour-associated antigens that are recognised by T cells [3].

Classification of tumour antigen	Mechanism of immune activation	Example
Cancer-testis antigens	Normal expression found in spermatocytes in testis (occasionally placenta), which is an immune-privileged site. Therefore, expression elsewhere in the body triggers T cell activation.	MAGE (melanoma antigen) BAGE (B antigen) GAGE (G antigen)
Differentiation antigens	Antigen is expressed by the tumour and the normal tissue from which it arose.	CEA – expressed in embryonic tissue and over-expressed in colorectal cancer. Gp100 – expressed in melanocytes and melanoma. PSA – expressed in normal prostate and over-expressed in prostate cancer.
Over-expressed tumour-associated antigens	Level of expression in normal tissue is below the threshold for T cell activation. Over-expression by malignant cells overrides tolerance and triggers T cell activation.	Her2 – over-expressed in breast cancer. AFP – over-expressed in hepatocellular cancer and certain germ cell tumours.
Tumour-specific antigens	These arise from genetic mutations or splicing aberrations, generating a protein that is foreign to the host immune system.	Mutant K-RAS in colorectal cancer.
Fusion proteins	Chromosomal translocation in certain tumours results in fusion of distant genes and expression of an abnormal fusion protein that is foreign to the host immune system.	BCR-ABL in CML and some ALL. EML4-ALK in non-small cell lung cancer.

CEA: carcinoembryonic antigen,

PSA: prostate specific antigen,

Her2: human epidermal receptor 2,

AFP: alpha-fetoprotein,

BCR-ABL: break point cluster region-Abelson,

EML4-ALK: echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase,

CML: chronic myeloid leukaemia,

ALL: acute lymphoblastic leukaemia.

Tumour immunology and clinical outcome

In many cancers there is a demonstrable correlation between level of immune cell infiltration and prognosis. Different populations of cells within the immune infiltrate affect prognosis in different ways. There are a lot of published data correlating prognosis with type of immune cell infiltrate. [Table 2](#) summarises some of the data.

Most recently it has been demonstrated that the higher the proportion of tumour infiltrating lymphocytes on core biopsy of breast cancer, the greater the likelihood of a pathological complete remission following neoadjuvant chemotherapy and Herceptin, in Her2-positive breast cancer. This data was reported at the 2013 San Antonio Breast Cancer Symposium where the team demonstrated a correlation between level of tumour-infiltrating lymphocytes and immune activation as well as clinical outcome, implying a pre-existing anti-tumour immunity. They also reported an association between high expression of inhibitory receptors PD-1 and CTLA-4, and benefit from Herceptin; hypothesizing that Herceptin overcomes tumour-mediated immunosuppression [24]. They used a mouse model of Her2-positive breast cancer to demonstrate improved efficacy of Herceptin when combined with a T-cell checkpoint inhibitor, compared to Herceptin alone [24].

Table 2. Correlation of immune cell infiltrate and clinical outcome.

Tumour Type	Immune Cell Infiltrate	Clinical Outcome
Associated with improved prognosis		
Melanoma	CD4 T cell infiltrate	Better survival and higher association with spontaneous tumour regression [6–8].
Breast cancer	Intra-tumoural T cell infiltrate, including CD8 T cells and Th1 CD4 T cells.	Improved survival and earlier stage disease [9–12].
Ovarian cancer	T cell infiltrate, including CD8 T cells.	Improved survival and reduction in VEGF [13–15].
Non-small cell lung cancer	CD4 and CD8 T cell infiltrate	Improved prognosis in early stage- and advanced stage disease [16, 17].
Associated with poor prognosis		
Breast cancer	High T _{reg}	Associated with poor prognosis disease (high-tumour grade, oestrogen receptor negative, lymph node positive) and reduced disease-free and overall survival [18, 19].
Melanoma	High T _{reg}	Increased recurrence rate [20].
Ovarian cancer	High T _{reg}	Associated with poor prognosis [14, 21].
Non-small cell lung cancer	High T _{reg}	Associated with increased risk of recurrence in resected early stage disease [22, 23].

The positive prognostic association of high CD4 and CD8 T cell infiltration within a tumour implies a clinically relevant anti-tumour immune response. This response is subject to down-regulation by inhibitory immune cells, including T_{Reg}. Therefore, tumours with high T_{Reg} infiltration may experience less of an anti-tumour immune response, hence the association with poorer clinical outcomes.

Targeting tumour antigens with antibodies

Targeting tumour antigens with antibodies is an established therapeutic for both solid tumours and haematological malignancies. There are different categories of tumour antigens that have been targeted by monoclonal antibodies. In haematological malignancies, antibodies have been raised against cluster of differentiation (CD) markers on T and B cells. In solid tumours, targets include growth factors, e.g., epidermal growth factor receptor (EGFR) and receptor activator of nuclear factor- κ B ligand (RANKL), as well as angiogenesis, e.g., vascular endothelial growth factor (VEGF).

There are several mechanisms by which antibodies cause tumour cell death. There is the direct action of the antibody, where binding of antibody to the cell causes receptor blockade. This inhibits the downstream signaling pathways within the cell, ultimately leading to apoptosis. Immune-mediated mechanisms include antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), where the Fc component (rather than the antigen-binding domain) of the antibody is most important. There is also the immune modulation of T cell function via inhibition of immune checkpoint proteins by targeted antibodies, e.g., anti-CTLA4 and anti-PD1.

Using Herceptin as an example, once the antibody has bound to Her2, expressed on the surface of a breast cancer cell, it prevents the dimerization of the receptor. Receptor dimerization is necessary for the activation of downstream signaling pathways. Herceptin inhibits the MAP kinase and PI3 kinase signaling pathways as well as causing cell cycle arrest, ultimately leading to apoptosis. The Fc component of Herceptin can trigger the innate immune response, in particular, NK cells which are directly cytotoxic to the tumour cell. Internalisation of Herceptin into the cell results in degradation of the antibody and presentation of antibody proteins to T cells via MHC. T cells are not only directly cytotoxic but will recruit other immune cells, including B cells, leading to ADCC. Finally, the Herceptin–Her2 complex results in activation of the complement pathway with binding of C1q to the antibody–antigen complex, resulting in cell lysis [25].

There are antibodies that have been conjugated to a radioisotope or cytotoxic agent to deliver these directly to the tumour cell in therapeutic doses. Conjugation of a radioisotope to antibody is used as a therapeutic in lymphoma. Most recently, T-DM1 (trastuzumab-emtansine) has shown clinical benefit in Her2-positive metastatic breast cancer where trastuzumab is conjugated to an anti-microtubule agent, emtansine. Upon ligand binding, the antibody conjugate becomes internalised into the cell enabling targeted delivery of a cytotoxin. This achieves delivery of a cytotoxic dose of a therapeutic agent directly to its target, whilst sparing healthy tissue, hence minimising toxicity [26].

Table 3 summarises examples of antibodies used in clinical practice, either NICE (National Institute for Health and Care Excellence) approved or available via the Cancer Drugs Fund (government funding of drugs not yet approved by NICE, available in England).

Table 3. Monoclonal antibodies used in clinical practice.

	Antigen	Antibody	Clinical Use
Angiogenesis	VEGF	Bevacizumab	Poor risk ovarian cancer [27, 28], triple negative breast cancer [29, 30], renal cell carcinoma [31], colorectal cancer [32–34], NSCLC(35).
Growth Factors	EGFR	Cetuximab	Head and neck squamous cell carcinoma [36], KRAS wild-type metastatic colorectal cancer [37–40].
	ERBB2	Herceptin	Adjuvant and metastatic Her2 positive breast cancer [41–43].
	ERBB2	Pertuzumab	Metastatic Her2 positive breast cancer [44].
	RANKL	Denosumab	Bone metastases secondary to solid tumours [45].
Haemopoietic antigens	CD20	Rituximab	Non-Hodgkin's lymphoma [46, 47].
	CD20	Ofatumumab	Refractory CLL [48].
	CD52	Alemtuzumab	CLL [49, 50].
	Proteasome inhibitor	Bortezomib	Myeloma [51].
	CD30	Brentuximab	Relapsed Hodgkin's lymphoma [52].
Conjugated Antibodies	CD20	⁹⁰ Y-labelled ibritumomab	Non-Hodgkin's lymphoma [53].
	CD20	¹³¹ I-labelled tositumomab	Non-Hodgkin's lymphoma [54, 55].
	ERBB2	T-DM1 - ERBB2-emtansine (antibody-drug conjugate)	Metastatic Her2 positive breast cancer [26].
Immunomodulatory	CTLA4	Ipilimumab	Metastatic melanoma [56].

NSCLC: non-small cell lung cancer,
CLL: chronic lymphocytic leukaemia.

Targeting immune checkpoint proteins with antibodies

Anti-CTLA4

Ipilimumab is a monoclonal antibody that blocks CTLA4 with the aim of promoting anti-tumour immunity. CTLA4 is expressed on T cells, where it serves to regulate the magnitude of the T cell response. Once the T cell receptor has bound target antigen, the co-stimulatory receptor CD28 amplifies T cell signaling. Activated T cells are not only directly cytotoxic but also act to recruit other components of both the innate and adaptive immune response. CTLA4 counteracts the activity of the CD28 receptor thus down-regulating individual T cells and preventing recruitment of other T and immune effector cells. T_{Reg} highly express CTLA4, which enhances their proliferation and immunosuppressive activity [57].

Ipilimumab has shown the greatest clinical activity in metastatic melanoma. The pivotal phase III trial demonstrating a survival benefit with ipilimumab was published in 2010. There were three arms in the trial, ipilimumab alone, ipilimumab with gp100 (melanoma cancer vaccine), and gp100 alone. The two arms treated with ipilimumab showed the same survival suggesting that the active agent was the ipilimumab. The patients treated with ipilimumab had a significant survival advantage to those treated with gp100 alone (10.1 months vs. 6.4 months, $p = 0.003$) [56]. Subsequent analyses have shown the survival benefits to be durable. A pooled analysis of 1,861 patients with melanoma treated with ipilimumab in 12 prospective and retrospective studies showed that 22% were still alive at 3 years, 17% were alive at 7 years, and the longest recorded survival in the database was 9.9 years [58].

The majority of toxicities experienced with ipilimumab were immune-related, mostly affecting skin and GI tract. Diarrhoea was the most common immune-related toxicity, occurring in 31% of patients. This manifested as frank colitis in some patients, requiring corticosteroids or infliximab (anti-TNF). Other immune-related events included skin rash, vitiligo, and endocrine insufficiencies (thyroid, pituitary, and adrenal) [56].

Anti-PD-1

PD-1 is expressed on T cells, particularly T_{Reg}, its expression being induced when T cells become activated. PD-1 primarily functions in peripheral tissues where T cells are exposed to the immunosuppressive PD-1 ligands, PD-L1 and PD-L2, that are expressed by tumour cells and surrounding stroma. Once PD-1 has bound one of its ligands, it functions to inhibit kinases responsible for T cell activation, except in T_{Reg} where binding of PD-1 to ligand enhances their proliferation [57, 59].

Blockade of PD-1 by anti-PD-1 antibody has been tested in phase I. The largest cohort tested included 296 patients with advanced solid tumours, including melanoma, NSCLC, renal cell carcinoma, prostate cancer, and colorectal cancer. Responses were observed in 20–25% of patients with NSCLC, renal cell carcinoma, and melanoma. No responses were observed in patients whose tumour specimens were negative for PD-L1. Similar to ipilimumab, responses were durable in some patients, with response duration of a year or more [59]. This is impressive given the fact that all patients were heavily pre-treated and no longer responding to conventional therapy.

The most common treatment-related toxicities seen with anti-PD-1 were fatigue, reduced appetite, diarrhoea, nausea, rash, and pruritus. Grade 3 or 4 treatment-related adverse events occurred in 14% of patients. Like ipilimumab, anti-PD-1 was associated with immune-related toxicity including pneumonitis, vitiligo, colitis, hepatitis, hypophysitis, and thyroiditis. There were three deaths from pulmonary toxicity [59].

There is ongoing interest in targeting PD-1 in different ways, for example, targeting one of the ligands with an anti-PD-L1 antibody, as well as combining blockade of PD-1 and CTLA4 [60].

Conclusion

The tumour microenvironment consists of a complex milieu of cells, including immune cells. Some components of the immune infiltrate exert a beneficial anti-tumour effect, while others can down-regulate host immunity, and promote tumour-immune evasion. The proportion of the different infiltrates within a tumour has been shown to affect clinical outcome.

Antibody therapy has successfully targeted tumour antigens for many years. Targeted antibodies exert their therapeutic effect not only by inhibiting the target but also by activation of the host immune system. There is now increasing interest in using antibodies to up-regulate host anti-tumour immunity with some durable results seen in early trials so far.

References

1. Fridman WH *et al* (Apr 2012) **The immune contexture in human tumours: impact on clinical outcome** *Nat Rev Cancer* **12**(4): 298–306 PMID: [22419253](#)
2. Janeway C (2005) *Immunobiology: the immune system in health and disease* 6th edn (Churchill Livingstone)
3. Novellino L, Castelli C and Parmiani G (March 2005) **A listing of human tumor antigens recognized by T cells: March 2004 update** *Cancer Immunol Immunother* **54**(3):187–207 PMID: [15309328](#)
4. Zou W, Chen L (Jun 2008) **Inhibitory B7-family molecules in the tumour microenvironment** *Nat Rev Immunol* **8**(6):467–77 PMID: [18500231](#)
5. Vignali DA, Collison LW and Workman CJ (July 2008) **How regulatory T cells work** *Nat Rev Immunol* **8**(7):523–32 PMID: [18566595](#) PMCID: [2665249](#)
6. Clemente CG *et al* (April 1 1996) **Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma** *Cancer* **77**(7) 1303–10 PMID: [8608507](#)
7. Hillen F *et al* (Jan 2008) **Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma** *Cancer Immunol Immunother* **57**(1):97–106 PMID: [17602225](#)
8. Tefany FJ *et al* (Aug 1991) **Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma** *J Invest Dermatol* **97**(2) 197–202 PMID: [1712819](#)
9. Alexe G *et al* (Nov 12 2007) **High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates** *Cancer Res* **67**(22) 10669–76 PMID: [18006808](#)
10. Mahmoud SM *et al* (May 2011) **Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer** *J Clin Oncol* **29**(15):1949–55 PMID: [21483002](#)
11. Marrogi AJ *et al* (Oct 21 1997) **Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma** *Int J Cancer* **74**(5) 492–501 PMID: [9355970](#)
12. Oldford SA *et al* (Nov 2006) **Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients** *Int Immunol* **18**(11) 1591–602 PMID: [16987935](#)
13. Kusuda T *et al* (Jun 2005) **Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.** *Oncol Rep* **13**(6) 1153–8 PMID: [15870936](#)
14. Sato E *et al* (Dec 20, 2005) **Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.** *Proc Natl Acad Sci USA* **102**(51) 18538–43 PMID: [16344461](#) PMCID: [1311741](#)

15. Zhang L *et al* (Jan 16 2003) **Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer** *N Engl J Med* **348**(3) 203–13 PMID: [12529460](#)
16. Al-Shibli KI *et al* (Aug 15 2008) **Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer** *Clin Cancer Res* **14**(16) 5220–7 PMID: [18698040](#)
17. Kawai O *et al* (Sep 15, 2008) **Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer** *Cancer* **113**(6) 1387–95 PMID: [18671239](#)
18. Bates GJ *et al* (Dec 1 2006) **Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse** *J Clin Oncol* **24**(34) 5373–80 PMID: [17135638](#)
19. Gobert M *et al* (Mar 1 2009) **Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome** *Cancer Res* **69**(5) 2000–9 PMID: [19244125](#)
20. Miracco C *et al* (Nov 2007) **Utility of tumour-infiltrating CD25+FOXP3+ regulatory T cell evaluation in predicting local recurrence in vertical growth phase cutaneous melanoma** *Oncol Rep* **18**(5) 1115–22 PMID: [17914561](#)
21. Hamanishi J *et al* (Feb 27, 2007) **Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer** *Proc Natl Acad Sci USA* **104**(9)3360–5 PMID: [17360651](#) PMCID: [1805580](#)
22. Petersen RP *et al* (Dec 15 2006) **Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients** *Cancer* **107**(12):2866-72 PMID: [17099880](#)
23. Shimizu K *et al* (May 2010) **Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer** *J Thorac Oncol* **5**(5) 585–90 PMID: [20234320](#)
24. Loi S MS and Salgado R *et al* (2013) **Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC)** *San Antonio Breast Cancer Symposium; San Antonio, USA*.
25. Nuti M and Bellati F *et al* (2011) **Immune effects of trastuzumab** *J Cancer* **2** 317–23 DOI: [10.7150/jca.2.317](#) PMID: [21716848](#) PMCID: [3119394](#)
26. Verma S *et al* (Nov 8 2012) **Trastuzumab emtansine for HER2-positive advanced breast cancer** *N Engl J Med* **367**(19) 1783–91 PMID: [23020162](#)
27. Burger RA *et al* (Dec 29, 2011) **Incorporation of bevacizumab in the primary treatment of ovarian cancer** *N Engl J Med* **365**(26) 2473–83 PMID: [22204724](#)
28. Perren TJ *et al* (Dec 29 2011) **A phase 3 trial of bevacizumab in ovarian cancer** *N Engl J Med* **365**(26) 2484–96. PMID: [22204725](#)
29. Miles DW *et al* (Jul 10 2010) **Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer** *J Clin Oncol* **28**(20) 3239–47 PMID: [20498403](#)
30. Miller K *et al* (Dec 27, 2007) **Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer** *N Engl J Med* **357**(26) 2666–76 PMID: [18160686](#)
31. Escudier B *et al* (May 1 2010) **Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival** *J Clin Oncol* **28**(13) 2144–50 PMID: [20368553](#)
32. Giantonio BJ *et al* (Apr 20 2007) **Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200** *J Clin Oncol* **25**(12)1539–44 PMID: [17442997](#)

33. Hurwitz H *et al* (Jun 3 2004) **Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer** *N Engl J Med* **350**(23) 2335–42 PMID: [15175435](#)
34. Saltz LB *et al* (Apr 20, 2008) **Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study** *J Clin Oncol* **26**(12) 2013–9 PMID: [18421054](#)
35. Reck M *et al* (Sep 2010) **Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)** *Ann Oncol* **21**(9) 1804–9 PMID: [20150572](#) PMCID: [2924992](#)
36. Bonner JA *et al* (Feb 9 2006) **Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck** *N Engl J Med* **354**(6) 567–78 PMID: [16467544](#)
37. Bokemeyer C *et al* (Feb 10 2009) **Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer** *J Clin Oncol* **27**(5) 663–71 PMID: [19114683](#)
38. Cunningham D *et al* (Jul 22 2004) **Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer** *N Engl J Med* **351**(4) 337–45 PMID: [15269313](#)
39. Karapetis C *et al* (Oct 23 2008) **K-ras mutations and benefit from cetuximab in advanced colorectal cancer** *N Engl J Med* **359**(17) 1757–65 PMID: [18946061](#)
40. Maughan TS *et al* (Jun 18 2011) **Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial** *Lancet* 2011 **377**(9783) 2103–14 PMID: [21641636](#) PMCID: [3159415](#)
41. Gianni L *et al* (Mar 12 2011) **Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial** *Lancet Oncol* **12**(3) 236–44 PMID: [21354370](#)
42. Slamon D *et al* (Oct 6 2011) **Adjuvant trastuzumab in HER2-positive breast cancer** *N Engl J Med* **365**(14):1273–83 PMID: [21991949](#) PMCID: [3268553](#)
43. Slamon DJ *et al* (Mar 15 2001) **Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2** *N Engl J Med* **344**(11)783–92 PMID: [11248153](#)
44. Baselga J *et al* (Jan 12 2012) **Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer** *N Engl J Med* **366**(2)109–19 PMID: [22149875](#)
45. Henry D *et al* (Oct 26 2013) **Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors** *Support Care Cancer* PMID: [24162260](#)
46. Coiffier B *et al* (Jan 24 2002) **CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma** *N Engl J Med* **346**(4) 235–42 PMID: [11807147](#)
47. McLaughlin P *et al* (Aug 1998) **Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program** *J Clin Oncol* **16**(8) 2825–33 PMID: [9704735](#)
48. Wierda WG *et al* (Nov 10 2011) **Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study** *Blood* **118**(19) 5126–9 PMID: [21856867](#)
49. Hillmen P *et al* (Dec 10 2007) **Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia** *J Clin Oncol* **25**(35) 5616–23 PMID: [17984186](#)
50. Keating MJ *et al* (May 15 2002) **Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study** *Blood* **99**(10) 3554–61 PMID: [11986207](#)

51. Oakervee HE *et al* (Jun 2005) **PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma** *Br J Haematol* **129**(6) 755-62 PMID: [15953001](#)
52. Younes A *et al* **Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma** *J Clin Oncol* **30**(18) 2183-9 PMID: [22454421](#) PMCID: [3646316](#)
53. Gordon LI, Molina A *et al* (Jun 15 2004) **Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study** *Blood* **103**(12) 4429-31 PMID: [15016644](#)
54. Kaminski MS *et al* (Oct 1 2001) **Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas** *J Clin Oncol* **19**(19) 3918-28 PMID: [11579112](#)
55. Press OW *et al* (Sep 1 2006) **Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911** *J Clin Oncol* **24**(25) 4143-9 PMID: [16896003](#)
56. Hodi FS *et al* (Aug 19 2010) **Improved survival with ipilimumab in patients with metastatic melanoma** *N Engl J Med* **363**(8) 711-23 PMID: [20525992](#) PMCID: [3549297](#)
57. Pardoll DM (Apr 2010) **The blockade of immune checkpoints in cancer immunotherapy** *Nat Rev Cancer* **12**(4) 252-64 PMID: [22437870](#)
58. From ECC2013 (Dec 2013) **Skin cancer: Ipilimumab-treated patients survive up to 10 years** *Nat Rev Clin Oncol* **10**(12) 669
59. Topalian SL *et al* (Jun 28 2012) **Safety, activity, and immune correlates of anti-PD-1 antibody in cancer** *N Engl J Med* **366**(26) 2443-54 PMID: [22658127](#) PMCID: [3544539](#)
60. Wolchok JD *et al* (Jul 11 2013) **Nivolumab plus ipilimumab in advanced melanoma** *N Engl J Med* **369**(2)122-33 PMID: [23724867](#)